Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DEEp Ocean Phase 3 trial of LP352 in developmental and epileptic encephalopathies
jRCT2011250051Phase 3Active, not recruiting
- Sponsor
- Lundbeck
- Start
- Nov 2025
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in epileptic encephalopathy and Lennox-Gastaut syndrome (LGS) comparing LP352 with Placebo (2 arms). Primary endpoint: Frequency percent change in countable motor seizures. Started Nov 2025; status: active, not recruiting.
02
Drugs
bexicaserin
03
Conditions
epileptic encephalopathyLennox-Gastaut syndrome (LGS)
Beyond the preview
Go deeper on jRCT2011250051.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2011250051.